Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130208 · ClinicalTrials.gov registry record · Phase 3
Effect of Sulodexide in Early Diabetic Nephropathy
A Phase 3 study, sponsored by Keryx Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,056
- Enrollment target
NCT00130208: Completed Phase 3 study, sponsored by Keryx Biopharmaceuticals.
NCT00130208 is a Phase 3 study that has completed, run by Keryx Biopharmaceuticals. The registered enrollment target is 1,056 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00130208, a Phase 3 study, has completed, sponsored by Keryx Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,056 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether treatment with sulodexide is effective in reducing the level of urine albumin excretion in patients with early diabetic kidney disease expressed as microalbuminuria.
Primary Outcome
The primary efficacy variable was the fraction of those patients in the ITT population with valid baseline and Week 26 ACRs in whom "therapeutic success" was achieved at Week 26 measured as a conversion of microalbuminuria to normoalbuminuria and at least a 25% reduction in ACR relative to baseline
Interventions
- DRUG Placebo
- DRUG Sulodexide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,056 participants |
| Start Date | 2005-08 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
What the finished NCT00130208 record still lists
NCT00130208 is an interventional study that assigns participants to a tested intervention. Its 1,056 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00130208 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00130208 about?
NCT00130208 is a clinical study titled "Effect of Sulodexide in Early Diabetic Nephropathy". The purpose of the study is to determine whether treatment with sulodexide is effective in reducing the level of urine albumin excretion in patients with early diabetic kidney disease expressed as microalbuminuria.
What is the current status of trial NCT00130208?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,056 participants. The study started on 2005-08. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00130208?
The interventions under investigation include: Placebo (DRUG), Sulodexide (DRUG).
Who is sponsoring clinical trial NCT00130208?
This trial is sponsored by Keryx Biopharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00130208's enrollment target sits among peer trials
1,056 277th of 2000 higher than 1,724 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03242642 · 1,056 participants · NA
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
- NCT04372108 · 1,056 participants
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
- NCT07018869 · 1,057 participants · Phase 3
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
- NCT03588286 · 1,058 participants · NA
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia